Tumor necrosis factor-α inhibitor-induced psoriasis: Systematic review of clinical features, histopathological findings, and management experience
- 1 February 2017
- journal article
- review article
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 76 (2) , 334-341
Abstract
No abstract availableKeywords
This publication has 110 references indexed in Scilit:
- Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatmentGut, 2013
- Histopathologic Spectrum of Psoriasiform Skin Reactions Associated With Tumor Necrosis Factor-α Inhibitor Therapy. A Study of 16 BiopsiesThe American Journal of Dermatopathology, 2010
- Tumor necrosis factor α blockade exacerbates murine psoriasis‐like disease by enhancing Th17 function and decreasing expansion of Treg cellsArthritis & Rheumatism, 2010
- Lichen planus–like eruptions: An emerging side effect of tumor necrosis factor-α antagonistsJournal of the American Academy of Dermatology, 2009
- Genetic Variations in Cytokines and Cytokine Receptors Associated with Psoriasis Found by Genome-Wide AssociationJournal of Investigative Dermatology, 2009
- A Randomized Trial of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients With Moderate-to-Severe Crohn's DiseaseGastroenterology, 2008
- A Genome-Wide Association Study Identifies IL23R as an Inflammatory Bowel Disease GeneScience, 2006
- Psoriasis induced by anti–tumor necrosis factor therapy: A paradoxical adverse reactionArthritis & Rheumatism, 2005
- Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease?Annals of the Rheumatic Diseases, 2003
- Psoriasis induced by interferon-αBritish Journal of Dermatology, 1991